Skyhawk Therapeutics, Inc. announced that it has entered into a second global strategic collaboration with an affiliate of Celgene Corporation. This new agreement follows the June 2018 collaboration between the two companies and focuses on targets relevant to the field of autoimmune disorders, oncology, and immuno-oncology, providing further validation of Skyhawk's proprietary SkySTARTM technology platform. The scope of the collaboration allows the parties to systematically interrogate a range of targets that have been clinically validated or are highly associated with the genetic basis of disease but have been considered undruggable using conventional small molecule therapies. Under the collaboration agreement, Skyhawk grants Celgene options to exclusively license worldwide intellectual property rights to candidates discovered and developed under the collaboration that are directed to program targets. Following Celgene's exercise of its option, Celgene will be responsible for further development and commercialization.